
|Articles|January 16, 2006
Subcutaneous IVIG now available
Advertisement
ZLB Behring has received FDA approval for the first subcutaneous immunoglobulin, Vivaglobin (Immune Globulin Subcutaneous [Human]), indicated for the treatment of patients with primary immunodeficiency. According to the company, patients can safely self-administer the immunoglobulin and the drug may be appropriate for those who cannot tolerate the intravenous products due to poor venous access or side effects. Portable pumps can be used by the patient to deliver their weekly doses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Pneumococcal Vaccination at 50 Years Old Can Improve Outcomes
5





























































